
Stock·NASDAQ·Healthcare
Natera, Inc. (NTRA)
- Market cap
- $39.64B
- P/E
- n/m
- Dividend yield
- No dividend
- Street target
- $405.00median of 22 analysts
- 52-week range
- $181.00 $437.41
What moved Natera, Inc. (NTRA)
Updated . Market figures as of November 20, 2026.
Was it the market or the company?
On November 20, 2026, NTRA fell 5.70%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.
The move was in line with the market. NTRA's one-year beta to SPY is 1.42, so SPY's -3.64% would on average have meant -5.17% for NTRA, close to what it did (0.5 percentage points more).
So most of the day's move came with the market; the dated news below is the company-specific backdrop, not the main driver of that session.
Over the last 20 sessions NTRA is down 32.32% against -9.23% for SPY, 23.1 percentage points behind it.
The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)
| That day | 5 sessions | 20 sessions | |
|---|---|---|---|
| NTRA | -5.70% | -14.32% | -32.32% |
| S&P 500 (SPY) | -3.64% | -8.56% | -9.23% |
| Nasdaq 100 (QQQ) | -5.67% | -10.51% | -13.62% |
| Health care sector (XLV) | -0.12% | -6.15% | -1.14% |
Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.
In the news
Investing.com reported that Natera used the Jefferies Global Healthcare Conference to lay out a larger growth plan while it manages a CEO transition. The company flagged near-term cost pressure, reimbursement work and a long runway to its revenue goals.
· Reported · Source: Investing.com
What changed since November 19, 2026
- CleaRank score: 47/100 on November 19, 2026, 45/100 on November 20, 2026 (still Hold).
After moves like this
NTRA fell 5.70% on November 20, 2026. Its typical daily move over the 60 trading days before was 1.35%. Between March 9, 2022 and November 20, 2026 (1,181 trading days) it fell at least that much in one day 36 times before.
| After the move | Cases | Median change | Range |
|---|---|---|---|
| 5 trading days later | 35 | +2.86% | -15.45% to +37.17% |
| 20 trading days later | 32 | +7.98% | -15.24% to +38.76% |
| 60 trading days later | 31 | +17.88% | -27.30% to +85.42% |
The close on November 20, 2026 is 37.29% below the highest close of the last 252 trading days ($436.00 on October 29, 2026). It is the lowest close since that high. Before that high, the last day it closed at least this far below its highest close of the 252 trading days to that day was October 30, 2023.
These figures describe what happened after earlier moves in that period. They are not a forecast.
NTRA stock today, November 22, 2026: price, news and analyst targets
As of November 20, 2026, Natera, Inc. (NTRA) trades at $273.40. Wall Street's median 12-month price target is $405.00 across 22 analysts, 48.1% above the price. CleaRank rates it Hold with a score of 45/100.
Natera's stock fell 5.70% on November 20, 2026, closing at $273.40, and now sits just 0.13% above its 200-day average of $273.05, the nearest support on the chart. The drop extends a sharp slide: the price is 27.19% below its 50-day average and 17.50% below its 20-day exponential average, with the 14-day RSI at 26.2, which places the stock in oversold territory. The sell-off comes after a 14.59% drop in the first session following the November 5, 2026 report, when adjusted EPS of -$0.42 missed the -$0.28 estimate by 50.00%. Analysts remain broadly positive, with 20 of 22 rating the stock Buy, and the median 12-month target is $405.00.
Why the stock has dropped
The stock has moved sharply lower over the past month, down 33.86%, after the November 5, 2026 report. Adjusted EPS of -$0.42 was a miss against the -$0.28 estimate, and the stock fell 14.59% in the first session after the report. The November 16, 2026 session also saw a 9.59% fall to $288.48, and the November 20, 2026 session took the close to $273.40. Investing.com reported on November 18, 2026 that Natera used the Jefferies Global Healthcare Conference to lay out a larger growth plan while managing a CEO transition, and that the company flagged near-term cost pressure, reimbursement work and a long runway to its revenue goals. The report is a press item and the company has not confirmed it, so the reasons for the sell-off are not settled.
Growth and profitability
Revenue grew 34.10% in the latest quarter compared with a year earlier, well ahead of the sector median of 8.1%. The company is still loss-making, with a net profit margin of -5.7% and an operating margin of -8.54%, and return on equity is -10.55%, below the sector median of 7.3%. Its debt-to-equity ratio is 0.13. Analysts expect revenue to rise 30.7% this fiscal year to about $3.0B, but they forecast EPS of -$1.56 for this year and -$0.35 for next year, so the path to profit is still a long way off.
Valuation against the sector
At $39.6B in market value and a price-to-sales ratio of 14.64, the stock trades at a premium to the sector median P/S of 3.4, a gap of 330.6%. The P/E ratio is not meaningful because reported earnings per share over the last 12 months are -$1.12. Insiders have sold $420.3M of stock over the last 18 months across 174 sales, with no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases would be.
CleaRank score 45/100 (Hold). 8 of 17 checks pass: trend 2 of 4, momentum 0 of 3, valuation and quality 0 of 3, analysts 3 of 3, track record 3 of 4.
About Natera
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners.
NTRA stock news
Growth plan and CEO transition
Investing.com reported on November 18, 2026 that Natera laid out a larger growth plan at the Jefferies conference while managing a CEO transition, and flagged near-term cost pressure and reimbursement work. The report is not company-confirmed, and the cost warning is the part most likely to weigh on the stock.
Earnings miss and sharp reaction
·Earnings report
Natera's adjusted EPS of -$0.42 on November 5, 2026 missed the -$0.28 estimate by 50.00%, and the stock fell 14.59% in the next session. This is the event that set the current downtrend.
Baird keeps Outperform
·Baird
Baird kept its Outperform rating on November 9, 2026, adding to the view that the analyst base remains supportive after the miss.
JP Morgan keeps Overweight
·JP Morgan
JP Morgan kept its Overweight rating on November 6, 2026, one day after the earnings report.
NTRA price target 2026
The base case is that the stock keeps trading in a wide range while it tests the 200-day average near $273.05. Holding that average would keep the trend intact, with the price above its 200-day average but below its 50-day one. A recovery toward the 20-day average near $331.39 would need the sell-off to ease and sentiment to steady after the earnings miss. Analysts' targets run from $280.00 to $500.00, with a median of $405.00, so the widest gap between the price and the analyst view remains. A close well below the 200-day average would put the 52-week low of $181.00 back in view and would challenge the analysts' revenue growth expectation of 30.7% for this fiscal year.
Analyst targets and ratings
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 9, 2026 | Baird | Maintains | Outperform |
| Nov 6, 2026 | JP Morgan | Maintains | Overweight |
| Nov 6, 2026 | Evercore ISI Group | Maintains | Outperform |
| Oct 27, 2026 | BTIG | Maintains | Buy |
| Oct 19, 2026 | Canaccord Genuity | Maintains | Buy |
| Oct 14, 2026 | JP Morgan | Maintains | Overweight |
NTRA support and resistance levels
Support sits first at the 200-day average of $273.05, which the price is testing now; a close below it would move the focus to the 52-week low of $181.00. Resistance comes first at the 20-day exponential average of $331.39, which the price sits well below. The next resistance is the 50-day average of $375.52, and the 52-week high of $437.41 is the furthest level above the price.
| Level | What it is | Price | From the price |
|---|---|---|---|
| Resistance 3 | 52-week high | $437.41 | +60.0% |
| Resistance 2 | 50-day moving average | $375.52 | +37.4% |
| Resistance 1 | 20-day exponential average | $331.39 | +21.2% |
| Price | November 20, 2026 | $273.40 | |
| Support 1 | 200-day moving average | $273.05 | -0.1% |
| Support 2 | 52-week low | $181.00 | -33.8% |
Technical indicators
NTRA technical analysis in depth
Volatility, momentum, trend strength and the price levels that matter for NTRA, calculated by CleaRank from daily bars to November 20, 2026.
Volatility
On the 20-day Bollinger Bands (2 standard deviations) the bands run from $242.31 to $452.34 around a middle of $347.32, and NTRA's close of $273.40 sits near the lower band.
The bands are wider than on 99% of the last 120 sessions: volatility is high for NTRA.
The 14-day average true range is $20.96, or 7.7% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 11.5% from the close.
Momentum and volume
The 14-day stochastic reads 1 (signal line 6): the close is near the bottom of its two-week range, an oversold zone.
The MACD line (12, 26) is -28.90 against a signal line (9) of -21.25, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 15 sessions ago.
Volume in the latest session was 0.6 times its 20-day average, a light session.
Trend strength
The 14-day ADX is 43: a trending market, with sellers in control (+DI 12, -DI 38).
On the weekly chart the 10-week average ($370.79) is above the 40-week average ($273.45), a rising longer-term trend, and the weekly RSI is 42.
Key levels
The nearest resistance from the price history is $299.01 (+9.4%): the price turned here 3 times, most recently on November 6, 2026.
The nearest support is $249.99 (-8.6%): the price turned here 6 times, most recently on July 29, 2026.
The largest swing of the last 120 sessions ran up from $204.16 (June 3, 2026) to $437.41 (October 6, 2026); the nearest Fibonacci retracement to the price is the 78.6% level at $254.08.
Classic pivot points for the next session, from November 20, 2026: pivot $277.89, resistance $283.92 and $294.44, support $267.37 and $261.33.
| Level | Price | From the price | What it is |
|---|---|---|---|
| Upper Bollinger Band | $452.34 | +65.4% | 20-day average + 2 standard deviations |
| Fibonacci 23.6% | $382.36 | +39.9% | retracement of the rise from $204.16 to $437.41 |
| Fibonacci 38.2% | $348.31 | +27.4% | retracement of the rise from $204.16 to $437.41 |
| Resistance (swing high) | $343.18 | +25.5% | a swing high set on August 27, 2026 |
| Resistance (swing high) | $321.01 | +17.4% | the price turned here 2 times, most recently on August 31, 2026 |
| Fibonacci 50.0% | $320.78 | +17.3% | retracement of the rise from $204.16 to $437.41 |
| Resistance (swing high) | $299.01 | +9.4% | the price turned here 3 times, most recently on November 6, 2026 |
| Pivot R2 (classic) | $294.44 | +7.7% | next-session level |
| Fibonacci 61.8% | $293.26 | +7.3% | retracement of the rise from $204.16 to $437.41 |
| Pivot R1 (Fibonacci) | $284.21 | +4.0% | 38.2% of the last range above the pivot |
| Pivot R1 (classic) | $283.92 | +3.8% | next-session level |
| Pivot point | $277.89 | +1.6% | average of the last high, low and close |
| Price | $273.40 | close, November 20, 2026 | |
| Pivot S1 (Fibonacci) | $271.56 | -0.7% | 38.2% of the last range below the pivot |
| Pivot S1 (classic) | $267.37 | -2.2% | next-session level |
| Pivot S2 (classic) | $261.33 | -4.4% | next-session level |
| Fibonacci 78.6% | $254.08 | -7.1% | retracement of the rise from $204.16 to $437.41 |
| Support (swing low) | $249.99 | -8.6% | the price turned here 6 times, most recently on July 29, 2026 |
| Lower Bollinger Band | $242.31 | -11.4% | 20-day average - 2 standard deviations |
| Support (swing low) | $221.59 | -19.0% | the price turned here 8 times, most recently on June 12, 2026 |
| Support (swing low) | $189.55 | -30.7% | the price turned here 8 times, most recently on May 15, 2026 |
Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.
NTRA stock price and trading
NTRA share price
NTRA fundamentals and valuation
Key statistics
NTRA against the Healthcare sector
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, NTRA trades at 13.63x, far above the sector median of 3.40x.
Return vs XLV: Since Jun 11, 2025, NTRA has gained 64.0% against a gain of 30.6% for XLV.
Performance against XLV
Revenue and earnings
Revenue growth: Revenue grew 35.9% in FY2025 to $2.3B, from $1.7B a year earlier.
Profit margin: The net margin was -9.0% in FY2025, up from -11.2% the year before.
Loss-making: NTRA lost $208M in FY2025.
Earnings reality check
Earnings record: NTRA beat the analyst estimate in 2 of the 6 reports in our data.
Market reaction: The stock fell in the first session after 1 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026after close | -$0.28 | -$0.42 | -50.00% | -14.59% | -11.22% |
| Aug 6, 2026after close | -$0.53 | -$0.47 | +11.32% | +21.37% | +17.11% |
| May 7, 2026after close | -$0.55 | -$0.60 | -9.09% | -11.64% | -10.42% |
| Nov 6, 2025after close | -$0.35 | -$0.64 | -82.86% | +0.55% | +1.10% |
| Aug 7, 2025after close | -$0.59 | -$0.74 | -25.42% | +7.70% | +12.31% |
| May 8, 2025after close | -$0.66 | -$0.50 | +24.24% | -6.53% | -8.10% |
NTRA price history and drawdowns
Risk profile
Worst falls and recoveries
Growth of $10,000
Against the market: NTRA beat the S&P 500 over this period: $232,879 against $36,764.
A $10,000 investment in NTRA in December 2016 would be worth about $232,879 today, compared with about $36,764 for the same investment in the S&P 500 benchmark with its dividends reinvested.
NTRA stock price prediction 2030
NTRA Stock Price Prediction 2030: Simulated Scenarios
CleaRank's simulation projects a price near $424 for NTRA by 2030 in the base case, from $273 today (1.6x over 4 years). The 10th-percentile path ends near $118. These are outcomes of a Monte Carlo simulation run on NTRA's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $161 | $305 | $579 | |
| 2028 | $138 | $341 | $843 | |
| 2029 | $125 | $380 | $1,154 | |
| 2030 | $118 | $424 | $1,529 |
NTRA insider trading
NTRA insider trading
Month by month
Net insider selling: No insider bought NTRA shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 6, 2026 | Jonathan Sheena
Director
|
Sell | 3.2K | $995.4K |
| Nov 3, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 795 | $314.0K |
| Nov 2, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 3.8K | $1.6M |
| Nov 2, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.4K | $1.4M |
| Nov 2, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 748 | $299.2K |
| Nov 2, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 341 | $136.4K |
| Nov 2, 2026 | John Fesko
President
|
Sell | 302 | $120.8K |
| Nov 2, 2026 | Jonathan Sheena
Director
|
Sell | 112 | $44.8K |
| Oct 28, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 5.7K | $2.4M |
| Oct 28, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 1.9K | $771.6K |
NTRA stock forecast: questions people ask
NTRA Forecast: Frequently Asked Questions
What is the NTRA stock forecast?
What is the NTRA price target?
Is NTRA a buy or sell today?
Why did Natera stock fall after its latest report?
How has NTRA performed over the past year?
Are insiders selling NTRA shares?
How risky is NTRA compared with the market?
How these figures are computed, and where the data comes from: CleaRank methodology.